ALDEYRA THERAPEUTICS INC (ALDX) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:ALDX • US01438T1060

5.48 USD
-0.08 (-1.44%)
At close: Feb 10, 2026
5.49 USD
+0.01 (+0.18%)
After Hours: 2/10/2026, 5:15:14 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Taking everything into account, ALDX scores 2 out of 10 in our fundamental rating. ALDX was compared to 523 industry peers in the Biotechnology industry. While ALDX seems to be doing ok healthwise, there are quite some concerns on its profitability. ALDX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year ALDX has reported negative net income.
  • ALDX had a negative operating cash flow in the past year.
  • In the past 5 years ALDX always reported negative net income.
  • In the past 5 years ALDX always reported negative operating cash flow.
ALDX Yearly Net Income VS EBIT VS OCF VS FCFALDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • ALDX has a Return On Assets of -55.52%. This is comparable to the rest of the industry: ALDX outperforms 45.51% of its industry peers.
  • The Return On Equity of ALDX (-87.71%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -55.52%
ROE -87.71%
ROIC N/A
ROA(3y)-37.64%
ROA(5y)-36.54%
ROE(3y)-50.36%
ROE(5y)-48.45%
ROIC(3y)N/A
ROIC(5y)N/A
ALDX Yearly ROA, ROE, ROICALDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

  • ALDX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALDX Yearly Profit, Operating, Gross MarginsALDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • The number of shares outstanding for ALDX has been increased compared to 1 year ago.
  • ALDX has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, ALDX has a worse debt to assets ratio.
ALDX Yearly Shares OutstandingALDX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ALDX Yearly Total Debt VS Total AssetsALDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • Based on the Altman-Z score of -2.73, we must say that ALDX is in the distress zone and has some risk of bankruptcy.
  • ALDX has a Altman-Z score (-2.73) which is comparable to the rest of the industry.
  • ALDX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.73
ROIC/WACCN/A
WACCN/A
ALDX Yearly LT Debt VS Equity VS FCFALDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

2.3 Liquidity

  • ALDX has a Current Ratio of 2.72. This indicates that ALDX is financially healthy and has no problem in meeting its short term obligations.
  • ALDX has a Current ratio of 2.72. This is in the lower half of the industry: ALDX underperforms 67.88% of its industry peers.
  • A Quick Ratio of 2.72 indicates that ALDX has no problem at all paying its short term obligations.
  • The Quick ratio of ALDX (2.72) is worse than 65.97% of its industry peers.
Industry RankSector Rank
Current Ratio 2.72
Quick Ratio 2.72
ALDX Yearly Current Assets VS Current LiabilitesALDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The Earnings Per Share has been growing slightly by 2.67% over the past year.
EPS 1Y (TTM)2.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • ALDX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.40% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y69.44%
EPS Next 2Y20.95%
EPS Next 3Y29.54%
EPS Next 5Y27.4%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALDX Yearly Revenue VS EstimatesALDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2023 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M
ALDX Yearly EPS VS EstimatesALDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • ALDX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALDX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALDX Price Earnings VS Forward Price EarningsALDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALDX Per share dataALDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ALDX's earnings are expected to grow with 29.54% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.95%
EPS Next 3Y29.54%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ALDX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ALDEYRA THERAPEUTICS INC

NASDAQ:ALDX (2/10/2026, 5:15:14 PM)

After market: 5.49 +0.01 (+0.18%)

5.48

-0.08 (-1.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05
Earnings (Next)02-26
Inst Owners57.55%
Inst Owner Change-1.3%
Ins Owners2.93%
Ins Owner Change0.05%
Market Cap329.68M
Revenue(TTM)N/A
Net Income(TTM)-43.19M
Analysts86.67
Price Target9.86 (79.93%)
Short Float %9.61%
Short Ratio4.5
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)41.76%
Min EPS beat(2)35.53%
Max EPS beat(2)47.98%
EPS beat(4)3
Avg EPS beat(4)26.62%
Min EPS beat(4)-17.52%
Max EPS beat(4)47.98%
EPS beat(8)5
Avg EPS beat(8)4.2%
EPS beat(12)9
Avg EPS beat(12)14.09%
EPS beat(16)13
Avg EPS beat(16)13.7%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)31.15%
EPS NY rev (1m)0%
EPS NY rev (3m)39.86%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.69
P/tB 6.69
EV/EBITDA N/A
EPS(TTM)-0.73
EYN/A
EPS(NY)-0.5
Fwd EYN/A
FCF(TTM)-0.67
FCFYN/A
OCF(TTM)-0.67
OCFYN/A
SpS0
BVpS0.82
TBVpS0.82
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -55.52%
ROE -87.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-37.64%
ROA(5y)-36.54%
ROE(3y)-50.36%
ROE(5y)-48.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.72
Quick Ratio 2.72
Altman-Z -2.73
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48%
EPS Next Y69.44%
EPS Next 2Y20.95%
EPS Next 3Y29.54%
EPS Next 5Y27.4%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y8.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year8.9%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y4.7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.7%
OCF growth 3YN/A
OCF growth 5YN/A

ALDEYRA THERAPEUTICS INC / ALDX FAQ

What is the fundamental rating for ALDX stock?

ChartMill assigns a fundamental rating of 2 / 10 to ALDX.


What is the valuation status of ALDEYRA THERAPEUTICS INC (ALDX) stock?

ChartMill assigns a valuation rating of 1 / 10 to ALDEYRA THERAPEUTICS INC (ALDX). This can be considered as Overvalued.


What is the profitability of ALDX stock?

ALDEYRA THERAPEUTICS INC (ALDX) has a profitability rating of 1 / 10.


What is the earnings growth outlook for ALDEYRA THERAPEUTICS INC?

The Earnings per Share (EPS) of ALDEYRA THERAPEUTICS INC (ALDX) is expected to grow by 69.44% in the next year.